From: Acute cardiac side effects after COVID-19 mRNA vaccination: a case series
Case | Age (years) | Sex | Vaccine | Comorbidity | First/second injection | Time onset of the cardiac reaction (days) | Treatment | Relief of symptoms (days) |
---|---|---|---|---|---|---|---|---|
1 | 13 | Male | Comirnaty©, BNT126b2 | No | Second | 3 | Observation, intermediate care | 5 |
2 | 28 | Male | Comirnaty©, BNT126b2 | No | Second | 2 | Observation | 7 |
3 | 28 | Male | Spikevax©, mRNA-1273 | Diabetes mellitus type 1 | First | 2 | Observation intermediate care | 3 |
4 | 56 | Female | Spikevax©, mRNA-1273 | Metabolic syndrome | Second | 2 | Observation | 7 |
5 | 42 | Male | Comirnaty©, BNT126b2 | No | Second | 2 | Observation | 7 |
6 | 42 | Male | Spikevax©, mRNA-1273 | No | Second | 10 | Observation intermediate care | 3 |
7 | 29 | Female | Comirnaty©, BNT126b2 | No | First | 1 | Observation intermediate care | 5 |
8 | 15 | Female | Comirnaty©, BNT126b2 | girdle muscle dystrophy type 2d | Second | 3 | Hospitalization | 5 |